A new startup is targeting a classic orthopedic issue: taking a proven, non-invasive technology (bone growth stimulation) that had gone […]
The theme running through this week’s deals, launches, and data drops is crystal clear: the entire musculoskeletal ecosystem is re-engineering
Your people are your company. Not the technology. Not the building. Not the logo, inventory, or income statement. Your employees
This is your wake up call. Most of our industry is still treating CMS payment changes like background noise. Big
Heads up Startup leaders! This could be the most important article that you will read this year. For an early-stage
There isn’t a good orthopedics solution for every patient—particularly in hips. Traditional ball-and-socket implants face persistent failure modes that remain
Observation The ortho venture space appears to be rewarding high-growth startup platforms that merge structural hardware with digital ecosystem integration.
When GLP-1 receptor agonists and those new multi-agonist weight-loss drugs started blowing up the headlines, the initial knee-jerk reaction across
You can’t make this stuff up. It’s real. There is an unbalanced incentive and punishment scale when defrauding Medicare in
Here’s a simple test that separates real startups from road kill: If your product disappeared tomorrow, would customers actively seek
Talented people in our industry often ask me for help with a big career decision. They’re usually trying to choose
There isn’t a good orthopedics solution for every patient. Particularly in knees. There is a massive, gaping hole in treatments.
This is the kind of week I like to see. No flashy billion-dollar distractions—just real companies solving real problems and
One simple metric is to measure the number of W2s per $1M of revenue. So what is appropriate as an
In our latest BoneChat roundtable, we I sat down with the king of strategic deals, Mike Minette. Read about Mike’s
If you’ve been tracking deal flow across orthopedics, spine, and regenerative medicine over the past few months, you’ve probably noticed
If you want to predict which ortho companies will scale and which will stall out in capital committees, ignore the
While most of the ortho world was looking the other way, MiMedx (MDXG) quietly pulled the trigger on acquiring Sanara
“Joint replacement is one of the most successful procedures in modern medicine… until the patient walks out of the OR.”
As we close out July 2026, our industry demonstrated steady momentum. Rather than large-scale venture funding rounds, activity centered on
Every orthopedic entrepreneur dreams of the endless upward slope. You build a strong first product, clear regulatory hurdles, win champion
If you follow the venture flow in orthopedics, you already know the era of the “me-too” implant is dead. Pure
I try to be useful for the ortho entrepreneur. The goal of this blog posting is simple: pull back the
Surgical hardware and digital intelligence are converging. In particular, we are watching ortho/spine market reach an inflection point, driven by
The past week highlighted key momentum across both U.S. and international orthopedic startups, marked by big M&A acquisitions, navigation clearances,
Agency is the real prize. Not status. Not the title. Not the salary line that shrinks with inflation every year
Let’s face it. All the innovation in orthopedics comes from startups these days. However, your better technology and better outcomes
This is really happening. Learn about it and beware. Let’s face it: the current capital-raising environment for early-stage orthopedic and
This is important… and often overlooked. In orthopedics, we love to talk about clinical data, disruptive tech, and market opportunity.
DePuy Synthes announced its acquisition of Expanding Innovations (EI), officially bringing the X-PAC® expandable interbody platform under the DPY umbrella.
This week we are shifting the Sports Med innovation discussion from passive bracing —> to predictive real-time knee protection. Historically,
Most of the industry is reading self-serving press releases, but here is your intel for the week. The trend continues
It is one of the most seductive pitches in modern venture capital: “We are going to disrupt Intuitive Surgical’s DaVinci.”
For decades, the dominant orthopedic corporate strategy was portfolio consolidation—creating “one-stop-shop” conglomerates that could bundle joints, spine, trauma, and sports
Article Summary The orthopedic industry just got handed a 10-year bill it can’t ignore. For decades, arthroscopic partial meniscectomy was
I believe that we are entering the Sports Med wave with accelerating innovation in this space. Here is my scoring
Most of the industry is reading self-serving press releases, but here is your intel on what really happened last week.
We’ve all heard the drumbeat: total hip arthroplasty (THA) is a mature, commodity market. Implants are reliable, survival curves flatline
We often talk about implant “commoditization” in orthopedics. It’s that spooky campfire story that consultants use to scare medical sales
Something different today. The orthopedic sector continues to showcase a fascinating divide of financial health. When looking at the public
The traditional playbook for taking an idea to commercialization is broken. Historically, a surgeon has a great new product idea
Tiger’s Strategic Summary ZB knows that implants are becoming commodities with an inevitable race to the bottom. ZB also knows
I believe that we are entering the Sports Med wave with accelerating innovation in this space. Below is my scoring of
Most of the industry is reading silly press releases, but here is your 7-day market update. Now that 2026 H1
I’m sharing this month’s DASHBOARD—the same intelligence I use to track new startups currently punching above their weight, M&A and
It’s been a rough few years for orthopedic innovators needed capital. My short summary of the capital allocators during this
If you’ve been in the orthopedics game long enough, you remember the Golden Era. Thirty years ago, being an ortho
What this article will teach you. Reimbursement isn’t a math problem; it’s a structural maze. Stop building your commercial strategy
You are looking at your offer letter from an early-stage orthopedic company. You can understand the base salary, the bonus
For decades, the sports medicine market has been defined by the same frustrating tradeoffs: mechanical weaknesses in repair setups, clunky
